相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New biological treatments for asthma and skin allergies
Stefanie Eyerich et al.
ALLERGY (2020)
Adverse events of benralizumab in moderate to severe eosinophilic asthma A meta-analysis
Wanshu Liu et al.
MEDICINE (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
Christina C. Kao et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer
Gilda Varricchi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc epsilon RI
Laura Maggi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2018)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Biology of Eosinophils and Their Role in Asthma
Claire N. McBrien et al.
FRONTIERS IN MEDICINE (2017)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?
Guy G. Brusselle et al.
LANCET RESPIRATORY MEDICINE (2016)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
Jennifer Namazy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Genetic risk factors for the development of allergic disease identified by genome-wide association
M. A. Portelli et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2015)
Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma
Rafael Firszt et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Role of Interleukin-13 in Asthma
Jonathan Corren
CURRENT ALLERGY AND ASTHMA REPORTS (2013)
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
Michael Noonan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort
Benedicte Leynaert et al.
THORAX (2012)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial
Nicola A. Hanania et al.
ANNALS OF INTERNAL MEDICINE (2011)
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer
Lucia De Monte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Airway remodelling in asthma: From benchside to clinical practice
Celine Bergeron et al.
CANADIAN RESPIRATORY JOURNAL (2010)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
A Large-Scale, Consortium-Based Genomewide Association Study of Asthma
Miriam F. Moffatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma
Prescott G. Woodruff et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The cytokine network in asthma and chronic obstructive pulmonary disease
Peter J. Barnes
JOURNAL OF CLINICAL INVESTIGATION (2008)
Induction of IL-4 expression in CD4+ T cells by thymic stromal lymphopoietin
Miyuki Omori et al.
JOURNAL OF IMMUNOLOGY (2007)
A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants
Shan L. Gyles et al.
IMMUNOLOGY (2006)
Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma
G. Hanf et al.
ALLERGY (2006)
Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells
LZ Xue et al.
JOURNAL OF IMMUNOLOGY (2005)
Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils
H Lin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Omalizumab-induced reductions in mast cell FcεRI expression and function
LA Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway
PT Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Mast-cell infiltration of airway smooth muscle in asthma
CE Brightling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
CD40 : CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes
A Bhushan et al.
IMMUNOLOGIC RESEARCH (2001)
分享论文
